Abzena PLC (LON:ABZA)‘s stock had its “buy” rating reaffirmed by analysts at FinnCap in a research report issued on Wednesday, May 24th. They presently have a GBX 80 ($1.02) target price on the stock. FinnCap’s price objective suggests a potential upside of 92.77% from the company’s current price.
A number of other equities analysts have also recently weighed in on ABZA. N+1 Singer reaffirmed a “corporate” rating on shares of Abzena PLC in a report on Thursday, April 6th. Numis Securities Ltd reaffirmed a “buy” rating and issued a GBX 90 ($1.15) price target on shares of Abzena PLC in a report on Tuesday, February 21st.
Abzena PLC (LON:ABZA) remained flat at GBX 41.50 during mid-day trading on Wednesday. The company had a trading volume of 108,667 shares. The stock’s market cap is GBX 57.21 million. The company’s 50-day moving average is GBX 37.60 and its 200-day moving average is GBX 37.17. Abzena PLC has a 52-week low of GBX 31.00 and a 52-week high of GBX 66.00.
WARNING: This article was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://sportsperspectives.com/2017/06/20/abzena-plc-abza-earns-buy-rating-from-finncap-updated-updated-updated.html.
Abzena PLC Company Profile
Abzena plc is a life sciences company. The Company provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups.
Receive News & Ratings for Abzena PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abzena PLC and related companies with MarketBeat.com's FREE daily email newsletter.